**Lexaria Bioscience Holds Successful Shareholder Meeting; Votes in New Directors and Approves Proposals**

Lexaria Bioscience Corp. (OTCMKTS:LXRP) recently announced the results of its annual and special shareholder meeting held on January 14, 2025. With 9,761,279 shares represented either in person or by proxy, constituting 55.93% of the company’s issued share capital as of November 18, 2024, various matters were voted upon with significant shareholder participation.

The voting results for the different matters were as follows:

– **Election of Directors:**
– Chris Bunka, John Docherty, Nicholas Baxter, Ted McKechnie, Albert Reese Jr., Richard Christopher, and Bal Bhullar were all elected as directors with approval rates ranging from 54% to 98%.

– **Appointment of Auditors:**
– Malone Bailey LLP was appointed as auditors with a resounding approval rate of 98%.

– **Executive Compensation Approval:**
– Approval for executive compensation and its frequency were also voted on. While the approval for executive compensation annually received a 32% approval rate, the option to approve it every two years, every three years, and the warrant exercise proposal garnered approval rates ranging from 1% to 70%.

– **Ratification of Directors’ Past Actions:**
– The shareholders ratified the lawful actions of the directors for the past year with a solid 91% approval rate.

It is worth noting that the percentages for each resolution were calculated based on abstained votes and broker non-votes not being counted as votes against the resolutions. The company had provided detailed descriptions of all proposals in its proxy statement filed with the Securities and Exchange Commission on November 27, 2024.

The Annual Meeting concluded successfully with a high level of shareholder engagement and approval for key decisions shaping the company’s governance and future direction. Lexaria Bioscience remains committed to transparency and accountability to its shareholders, ensuring continued growth and success in the biotechnology sector.

—

This article is based on the 8-K SEC Filing submitted by Lexaria Bioscience Corp. on January 14, 2025.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Lexaria Bioscience’s 8K filing here.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries.